Continuing Education Activity
This topic is about cytoreduction surgery using hyperthermic intraperitoneal chemotherapy (HIPEC), representing a concept of multimodal therapy increasingly used to manage peritoneal carcinoma. There are different therapeutic options available for patients with peritoneal carcinoma, but this topic will be about using HIPEC. This activity describes and explains the interprofessional team's role in improving care for patients who undergo HIPEC.
Objectives:
Describe the technique of hyperthermic intraperitoneal chemotherapy.
Identify the indications for hyperthermic intraperitoneal chemotherapy.
Summarize the risks and benefits associated with hyperthermic intraperitoneal chemotherapy.
Outline some interprofessional team strategies that can be employed to ensure optimal outcomes for patients who need hyperthermic intraperitoneal chemotherapy performed.
Introduction
While primary peritoneal mesothelioma rarely occurs, peritoneal carcinomatosis: PC (tumor infiltration of the peritoneum) is most commonly seen in abdominopelvic malignancies. It is a common manifestation in gastrointestinal and gynecological tumors during tumor disease because several gastrointestinal and gynecological malignancies have the potential to progress into the peritoneal cavity.
Several risk factors can be cited: locally advanced carcinoma, mucosal tumors, tumor perforation, and tumor opening during resection.
In colorectal cancer, the peritoneum is the second most common metastatic site and has a poor prognosis with a median survival of 6 to 9 months without treatment.[1]
According to population-based studies, colorectal peritoneal carcinomatosis prevalence varies between 5% to 10% in patients with colorectal cancer.[2]
Globally and each year, 240,000 women are diagnosed with ovarian cancer, and epithelial carcinomas account for about 90% of all cases. Due to its clinical presentation often and unfortunately in advanced stages, ovarian cancer is classified as a malignancy of the peritoneal surface.[3]
Primary forms, such as peritoneal mesothelioma and peritoneal carcinoma, must be differentiated from the peritoneal spread of malignant tumors, either gastrointestinal tract or ovarian; amedian survival of 6 months for colorectal cancer and 3 months for gastric cancer shows a clearly limited prognosis. Results for peritoneal mesothelioma with systemic chemotherapy are similar.The probability of survival is better for advanced ovarian cancer, for which a median survival of up to 2 years is possible.
Treatment should be multimodal and include preoperative systemic chemotherapy, complete cytoreductive surgery, and intraabdominal hyperthermia combined with intraoperative chemotherapy.
Thus the complete surgical cytoreduction possible is decisive for the prognosis, which requires multiple organ resections in addition to a partial to subtotal parietal peritonectomy.
To quantify the extent of peritoneal metastases and determine the feasibility of tumor reduction, a surgical variable is used (index of peritoneal carcinomatosis: PCI). Indeed, depending on the pathologies, there is a threshold value beyond which the procedure does not improve survival.[4]
In addition to an excessively high PCI, the invasion of certain sites also contraindicates cytoreduction surgery. These are the root of the mesentery, the hepatic pedicle, the retroperitoneum, and the bladder. Major damage to the small bowel, which potentially could induce short bowel syndrome, is also a contraindication.
Complete macroscopic cytoreduction is the basis for successful multimodal therapy.
First described by Spratt in 1980 in animal experiments and known as a thermal transfusion infiltration system,hyperthermic intraperitoneal chemotherapyrepresents a concept of multimodal therapy increasingly used in the management of peritoneal carcinoma andmore in the following decades and is now an integral part of the treatment of primary and secondary peritoneal tumors. This involves administering cytotoxic agents into the peritoneal cavity at an elevated temperature (41 to 43degrees C) to promote their absorption by neoplastic nodules.[5]
Hyperthermic intraperitoneal chemotherapy (HIPEC) has become the treatment of choice for treating peritoneal metastases from ovarian, stomach, or colorectal cancers.
Nowadays, surgical cytoreduction combined with hyperthermic intraperitoneal chemotherapy (CRS / HIPEC) has radically changed the approach of patients with malignant tumors of the peritoneum, which has improved the prognosis of appendicular, colorectal, and ovarian tumors, as well as peritoneal mesothelioma.[6][7]
This topic explains and describes the principles and importance of HIPEC in the concept of multimodal therapyfor patients with malignant tumors of the peritoneum.
Anatomy and Physiology
Like the tumor entity, the extent of intra-abdominal tumor invasion is crucial for operability and prognosis. Intra-abdominal tumor burden is determined using the Sugarbaker Peritoneal Carcinosis Index. The abdomen is divided into 12 regions, the last 4 of which describe the small intestine, and individual lesions are classified according to their size.
After administration of cytotoxic drugs in the intra-abdominal cavity, a difference in the concentration of the cytotoxic agent is observed between the peritoneal cavity and the plasma,related to the relatively slow movement of the drug from the peritoneal cavity to the plasma (peritoneal clearance) andexplained by the existence of a peritoneal-plasma barrier (Sugarbaker 1996).[8]
Curiously, the pharmaco*kinetics of intraperitoneal chemotherapy is not affected by surgical removal of the diseased peritoneum.[9]
Blood drainage from the peritoneal surface occurs via the portal vein to the liver, providing increased exposure of potential liver micrometastases to cytotoxic drugs.[10]
Higher drug concentrations in lymph than in plasma are observed because the lymphatics transport some drugs to the systemic circulation, representing a second beneficial effect of intraperitoneal chemotherapy.
Some authors (Van der Speeten K et al. ) refer to a three-compartment model that includes the tumor-bearing peritoneum as the third compartment, where the drug is incorporated by tissue penetration.[11]
The association of hyperthermia is justified by the fact that malignant cells are selectively destroyed by hyperthermia in the range of 41to 43degrees C.[12][13]Additionally, the microcirculation in most malignant tumors exhibits complete vascular stasis in response to hyperthermia. The combination of heat and cytotoxic drugs results in increased cytotoxicityresulting in increased drug absorption into malignant cells due to increased membrane permeability.[14]The most important effect of hyperthermia is, therefore, the synergistic effect with certain cytostatics. A synergistic effect has been described for doxorubicin, cytostatics containing platinum, mitomycin C, melphalan, docetaxel, irinotecan, and gemcitabine (Sugarbaker PH et al.)[15]
Indications
In addition to the surgical operability criteria and the comorbidity factors taking into account ASA classification (ASA score [American Society of Anesthesiologists] <3), hepatic and renal function and the cumulative dose of chemotherapy treatments must be considered.
In gastric adenocarcinoma,peritoneal carcinomatosis is very common; even after radical surgery,cytoreduction surgery with CHIP seems to delay oncological progression without affecting long-term survival. The procedure remains in the experimental field and should be reserved for younger patients under the age of 60, who are active, with a PCI <10 and small nodules, without ascites, extraperitoneal metastasis, orhepatic invasionthat has responded well to neoadjuvant chemotherapy.[16][17]
According to a review of the literature and meta-analysis, cytoreduction surgery with HIPEC prolongs overall survival and up to eight years after the gesture in ovarian neoplasia with peritoneal carcinosis.[18]
In colorectal cancer:the peritoneum is the second site most common metastatic after the liver, about 7 to 15% of colorectal cancer patients have synchronous PC, and 4to 19% will develop one afterward.
An improvement in patient prognosis has been noticed since the introduction of cytoreduction surgery with HIPEC and modern chemotherapy regimens (capecitabine, oxaliplatin, irinotecan) combined with immunotherapy (bevacizumab, cetuximab, panitumumab).[19][20]
Peritoneal pseudomyxoma and mucinous tumors of the appendix: Cytoreduction surgery (CRS) with HIPEC has been well established as the only treatment for mucinous tumors with peritoneal dissemination, based on retrospective and comparative studies (Chua et al.).[21]
Mesothelioma:Mesothelioma is a rare tumor of peritoneal origin. Cytoreduction surgery combined with HIPEC improves mean survival by up to 4 years but with repeated procedures.[22]
Contraindications
It has been shown by several studies that when the surgical cytoreduction is incomplete, there is no longer any benefit from HIPEC on survival.[23]
Medically, in addition to comorbid factors such as severe cardiovascular disorders and serious lung disease, hepatic and renal failure may complicate the procedure and should contraindicate the operation.
Allergy to cytotoxic agents is a formal contraindication to the HIPEC.
The threshold value of the PCI score to perform aHIPEC in the PC of colorectal origin is 20. Indeed, the survival overall at five years is virtually zero for patients with a PCI greater than 20.[24]
Surgicallyand in addition to a too high PCI score, the invasion of some surgical sites also contraindicates the HIPEC. These are the root of the mesentery, the hepatic pedicle, retroperitoneum, and the bladder.Impairment of small intestinal function that potentially could induce a shortbowel syndrome is also a contraindication.
Ultimately, surgical cytoreduction will remove as many tumors as possible, while the associated HIPEC will make it possible to "sterilize" the tumor residues not visible to the naked eye. The purpose of CHIP is to obtain a high local concentration of chemotherapy and a low systemic concentration.[16]
Equipment
Before starting this procedure in a hospital, it is mandatory to have a chemotherapy approval infrastructure equipped with a surgical infrastructure linked to the medical-surgical resuscitation unit for patient monitoring.
HIPEC can be performed on the open and closed abdomen. In both perfusion models, the abdominal cavity is continuously perfused with cytostatic solution heated to 41to 43degrees C through a drainage system consisting of inlet and outlet catheters.
This procedure, therefore, requires the following equipment:
A heat exchangerconnected to a thermostat to maintain a stable temperature at 42degrees in the extracorporeal circulation
Outflow and inflow catheterto ensure the infusion and absorption of the cytotoxic drug in the abdominal cavity
Temperature probeswhich measure the temperature in the circuit and the peritoneum
Roller pumpto maintain the extracorporeal circulation of the cytotoxic drug
The reservoir of the cytotoxic agent
A computer system that controls the heat exchanger and the drainage pumps according to the thermal probes
A timer that measures the infusion time
Cytotoxic drugs used for intra-abdominal chemotherapy are mitomycin C, Platine, doxorubicin, pacl*taxel, and irinotecan.
The chemotherapeutic agent is applied with a carrier solution (mainly 0.9% NaCl or 5% glucose). The volume of the carrier solution is calculated based on the body surface area.Usually, infusion volumes between 1.5 and 2 liters/ m^2 of body surface areas are used.
Personnel
HIPEC is an intraperitoneal chemotherapy technique that should only be performed by qualified physicians who have received sufficient training in surgical oncology. Nursing staff in the operating room must be qualified, trained in medical oncology, and manage the extracorporeal circulation of cytotoxic drugs during this procedure to perform the procedure safely.
Hospital pharmacists must prepare cytotoxic drugs at the pharmacy in a specific room under constant laminar flow to strictly reduce any bacterial contamination of the preparation.
Preparation
Before initiating the procedure, a preoperative evaluationis necessary according to WHO guidelines. This evaluation must include the medical-surgical history, the assessment of tumor generalization, the history of preoperative or neoadjuvant chemotherapy, and the analysis of cardiopulmonary examinations. Current treatment should also be noted, including the consumption of anti-coagulants to minimize the risk of bleeding during surgical cytoreduction because it is a major surgery that will precede the act of HIPEC.
The patient must understand the advantages and disadvantages of the operation as well as the benefit/risk ratio of HIPEC because the procedure must be able to improve the survival of the oncological patient. A detailed description of the procedure is required to obtain informed consent from the patient.
The role of the anesthetist is essential during cytoreduction and HIPEC. Specific training is desirable.
Finally, this procedure must be performed in a qualified university center specializing in medico-surgical oncology and equipped with an appropriate medical surveillance infrastructure.
Technique or Treatment
Generally, two methods for HIPEC are described: open abdomen technique and closed abdomen technique.
Open abdomen technique: as described by Sugarbaker, at the end of the surgical cytoreduction, a Tenckhoff catheter and four closed suction drains are sutured to the skin and placed through the abdominal wall. The temperature probes are attached to the skin edgefor intraperitoneal temperature monitoring.The skin edges at the level of the abdominal incisions are suspended until the Thompson self-retaining retractorby a monofilament to maintain open space in the abdominal cavity. For preventing the leakage of the chemotherapy solution, a plastic sheet is inserted into this suture.
Continuous manipulation by the surgeon of the perfusion allows theuniform exposure of all anatomical structures to heat and chemotherapy during the procedure. A pumping system injects the chemotherapy infusion into the abdomen through the Tenckhoff catheter and pulls it through the drains with a constant flow. The heat exchanger keeps the intraperitoneal fluid temperature at 41to 43degrees, the drug is then administered in the circuit, and the timer for the perfusion is started. The duration varies from 30 min to 1 hour, depending on the type of cancer.
A disadvantage of the open technique is the heat dissipation, making it more difficult to have a hyperthermic state.
Closed abdomen technique: Thermal catheters and probes are placed in the same way, but the skin edges of the laparotomy are tightly sutured to allow perfusion in a closed circuit.The abdominal wall is shaken manually by the surgeon during the infusion for uniform heat distribution. The volume of perfusate is greater in this technique to establish the circuit, and higher abdominal pressure is obtained during the perfusion, which facilitates tissue penetration of the drug. After infusion, the abdomen is reopened to remove the perfusate and the preparation of the anastomosis. This technique allows maintaining rapid attainment of hyperthermia because there is minimal heat loss.
Complications
According to recent studies (meta-analysis), Cytoreductive surgery and HIPEC are associated with morbidity and mortality of approximately 33% and 2.8%, respectively.[25]It should be remembered that heavy and complex surgical procedures likely lead to increased toxicity of HIPEC through changes in pharmaco*kinetics, protein losses, hepatic and renal metabolic restrictions, and stress-related bone marrow suppression.[26]According to the literature, this increased toxicity is manifested by hematotoxicity and nephrotoxicity with respective frequencies of 5.6% and 1.7%.[25]
Particular complications associated with the procedure are prolonged intestinal atony, increased fluid movement over the abdomen, delayed wound healing, and prolonged hospitalization.
Cases of intrathoracic chemotherapy have been described in cases of major surgery with diaphragm perforation.
Have been identified as risk factors for this procedure's serious complications: the general condition of the patient, age, the extent of peritoneal carcinoma, duration of the intervention, number of peritonectomy procedures, number of anastomoses, the quality of cytoreduction, and the dosage of intraperitoneal chemotherapy.
Other complications have been observed which are not related only to theHIPEC but are well associated with cytoreduction: Pancreatitis, fistula, Pulmonary embolism, and thrombosis.
Clinical Significance
According to several clinical studies, infiltration of the abdominal cavity by neoplastic cells is inevitable following surgical manipulation during peritonectomy. The main goal of intraperitoneal chemotherapy is to eliminate these free tumor cells and any micrometastases that are not visible to the naked eye. Classically, HIPEC is performed after surgical resection and before reconstruction of the gastrointestinal tract. This potentially curative therapeutic option completes the concept of multimodal therapy, andit is increasingly needed for patients with peritoneal metastatic gastrointestinal and gynecological tumors and mainly peritoneal malignancies.
Several prospective studies have proven the superiority of the concept of multimodal therapy over a single systemic therapy in the treatment of metastatic cancers.[27][28][29]
Van Driel et al. published in the New England journal of medicine the results of a multicenter randomized study on the treatment of peritoneal carcinoma in ovarian carcinoma. A statistically significant advantage was clearly demonstrated for the combined treatment compared to cytoreduction alone, especially in improving patient survival.[29]
For peritoneal carcinoma of colorectal origin, Quenet et al. included a prospective randomized study of 265 patients over a period of 6 years who should benefit from HIPEC versus a comparator group with simple cytoreduction; the results are statistically significant. The survival of patients who underwent HIPEC with a PCI score between 11 and 15 was better.[30]It should be noted that many oncological centers consider that PCI> 20 is considered an exclusion criterion for HIPEC in colorectal cancer, and the PCI value of 15 is currently considered the upper limit of sensitive multimodal therapy.[31]
Despite the widespread use of HIPEC by several oncology centers, there is no consensus described on the method used, particularly the combinations of cytostatics, the concentration of cytostatics, the application time, the temperature, the infusion volume, and infusion duration, and optimal infusion mode.[32]
According to several retrospective studies, the combination of chemotherapy, whether systemic or peritoneal, with surgical cytoreduction is still beneficial.[33][34][35]
However, perioperative systemic chemotherapy's benefits in initially resectable peritoneal metastases of colorectal cancer remain a subject of discussion. According to a recent study (Deborah J Reppulo et al., 2021), a retrospective analysis of 125 patients treated with complete CRS and HIPEC for Peritoneal malignancy (PM) from the colorectal originwith or without perioperative systemic chemotherapy (PCT). In this study, the authors do not show any clear benefit of PCT in carefully selected patients undergoing CRS and HIPEC for colorectal PM.[36]
Concerning gastric tumors with peritoneal carcinomatosis, the prognosis is limited. The median survival of only 7 months improved after cytoreductive surgery to 12 months on average; in some studies, additional HIPEC has shown beneficial effects on survival.[37][38][39]
For mucinous tumors with peritoneal dissemination, CRS / HIPEC has been well defined as the only effective treatment, based on retrospective and comparative studies (Chua TC et al. 2012),with an improvement in median survival up to 16.3 years.[21]
Enhancing Healthcare Team Outcomes
HIPEC, often combined with surgical cytoreduction, is a heavy procedure with a non-negligible morbidity and mortality rate even in the most efficient centers; it must be performed in university centers specializing in oncological surgery with multimodal and multidisciplinary care. This also implies collaboration between inter-professional teams.
The oncologist must respect the correct selection of patients in agreement with the surgeon to perform this procedureby taking into account the beneficial effects of HIPEC on the long-term survival of the oncological patientwithout forgetting the benefit/risk ratio.
The anesthesiologist should perform a preoperative evaluation necessary for the patient's operability. The resuscitator in charge of the intensive care unit must be informed of the procedure and its complications before admission to the intensive care unit.
Nursing, Allied Health, and Interprofessional Team Interventions
To perform a HIPEC safely, aqualified nursing team for the operating room and postoperative recovery is needed. Nurses must be trained in intensive care units and in the operating room to be able to manage intraoperative and postoperative complications without difficulty.
Nursing, Allied Health, and Interprofessional Team Monitoring
HIPEC must be carried out in university centers equipped with invasive vital signs monitoring devices for optimal monitoring of vital parameters and management of complications related to both surgery and the toxicity of cytotoxic drugs.This involves invasive monitoring of the arterial pressure curve, monitoring of central venous pressure, cardiac output, and peripheral vascular resistance.
References
- 1.
März L, Piso P. Treatment of peritoneal metastases from colorectal cancer. Gastroenterol Rep (Oxf). 2015 Nov;3(4):298-302. [PMC free article: PMC4650975] [PubMed: 26424828]
- 2.
Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012 May;99(5):699-705. [PubMed: 22287157]
- 3.
Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14. [PubMed: 27743768]
- 4.
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-74. [PubMed: 8849962]
- 5.
Spratt JS, Adco*ck RA, Sherrill W, Travathen S. Hyperthermic peritoneal perfusion system in canines. Cancer Res. 1980 Feb;40(2):253-5. [PubMed: 7356508]
- 6.
Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008 Sep;15(9):2426-32. [PubMed: 18521686]
- 7.
Klaver CE, Groenen H, Morton DG, Laurberg S, Bemelman WA, Tanis PJ., research committee of the European Society of Coloproctology. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. Colorectal Dis. 2017 Mar;19(3):224-236. [PubMed: 28008728]
- 8.
Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53-63. [PubMed: 8849943]
- 9.
de Lima Vazquez V, Stuart OA, Mohamed F, Sugarbaker PH. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmaco*kinetics. Cancer Chemother Pharmacol. 2003 Aug;52(2):108-12. [PubMed: 12759776]
- 10.
Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW, Myers CE. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res. 1981 May;41(5):1916-22. [PubMed: 7214359]
- 11.
Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmaco*kinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J. 2009 May-Jun;15(3):216-24. [PubMed: 19556908]
- 12.
de Bree E, Helm CW. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data. Expert Rev Anticancer Ther. 2012 Jul;12(7):895-911. [PubMed: 22845405]
- 13.
Oseledchyk A, Zivanovic O. Intraoperative Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer. Oncology (Williston Park). 2015 Sep;29(9):695-701. [PubMed: 26384807]
- 14.
de Bree E, Tsiftsis DD. Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. Recent Results Cancer Res. 2007;169:39-51. [PubMed: 17506248]
- 15.
Brown SL, Hunt JW, Hill RP. Differential thermal sensitivity of tumour and normal tissue microvascular response during hyperthermia. Int J Hyperthermia. 1992 Jul-Aug;8(4):501-14. [PubMed: 1402130]
- 16.
Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol. 2016 Jan 21;22(3):1114-30. [PMC free article: PMC4716024] [PubMed: 26811651]
- 17.
Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, Yonemura Y, Ansaloni L. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014 Jan;40(1):12-26. [PubMed: 24290371]
- 18.
Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: Asystematic review and meta-analysis. Eur J Surg Oncol. 2015 Dec;41(12):1578-89. [PubMed: 26453145]
- 19.
Klos D, Riško J, Stašek M, Loveček M, Hanuliak J, Skalický P, Lemstrová R, Mohelníková BD, Študentová H, Neoral Č, Melichar B. Current status of cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) in the multimodal treatment of peritoneal surface malignancies. Cas Lek Cesk. 2018 Dec 17;157(8):419-428. [PubMed: 30754979]
- 20.
Garland-Kledzik M, Uppal A, Naeini YB, Stern S, Erali R, Scholer AJ, Khader AM, Santamaria-Barria JA, Cummins-Perry K, Zhou Y, Votanopoulos KI, Shen P, Levine EA, Bilchik AJ. Prognostic Impact and Utility of Immunoprofiling in the Selection of Patients with Colorectal Peritoneal Carcinomatosis for Cytoreductive Surgery (CRS) and Heated Intraperitoneal Chemotherapy (HIPEC). J Gastrointest Surg. 2021 Jan;25(1):233-240. [PMC free article: PMC8936024] [PubMed: 33269456]
- 21.
Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012 Jul 10;30(20):2449-56. [PubMed: 22614976]
- 22.
Dehal A, Smith JJ, Nash GM. Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future. J Gastrointest Oncol. 2016 Feb;7(1):143-57. [PMC free article: PMC4754310] [PubMed: 26941992]
- 23.
Lambert LA. Looking up: Recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin. 2015 Jul-Aug;65(4):284-98. [PubMed: 25940594]
- 24.
da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006 Dec;203(6):878-86. [PubMed: 17116556]
- 25.
Piso P, Nedelcut SD, Rau B, Königsrainer A, Glockzin G, Ströhlein MA, Hörbelt R, Pelz J. Morbidity and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Data from the DGAV StuDoQ Registry with 2149 Consecutive Patients. Ann Surg Oncol. 2019 Jan;26(1):148-154. [PubMed: 30456672]
- 26.
Elias D, Raynard B, Boige V, Laplanche A, Estphan G, Malka D, Pocard M. Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. J Surg Oncol. 2005 Jun 15;90(4):220-5. [PubMed: 15906364]
- 27.
Morano WF, Khalili M, Chi DS, Bowne WB, Esquivel J. Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions-A systematic review. J Surg Oncol. 2018 Feb;117(2):245-259. [PMC free article: PMC6692902] [PubMed: 29120491]
- 28.
Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011 Jun;18(6):1575-81. [PMC free article: PMC3087875] [PubMed: 21431408]
- 29.
van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger Lfa*g, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018 Jan 18;378(3):230-240. [PubMed: 29342393]
- 30.
Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, Marchal F, Loi V, Meeus P, Juzyna B, de Forges H, Paineau J, Glehen O., UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):256-266. [PubMed: 33476595]
- 31.
Hompes D, D'Hoore A, Van Cutsem E, Fieuws S, Ceelen W, Peeters M, Van der Speeten K, Bertrand C, Legendre H, Kerger J. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. Ann Surg Oncol. 2012 Jul;19(7):2186-94. [PubMed: 22395983]
- 32.
Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, Nash G, Morse M, Adbel-Misih R, Alexander HR, Attiyeh F, Bartlett D, Bastidas A, Blazer T, Chu Q, Chung K, Dominguez-Parra L, Espat NJ, Foster J, Fournier K, Garcia R, Goodman M, Hanna N, Harrison L, Hoefer R, Holtzman M, Kane J, Labow D, Li B, Lowy A, Mansfield P, Ong E, Pameijer C, Pingpank J, Quinones M, Royal R, Salti G, Sardi A, Shen P, Skitzki J, Spellman J, Stewart J, Esquivel J. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014 May;21(5):1501-5. [PubMed: 23793364]
- 33.
Désolneux G, Mazière C, Vara J, Brouste V, Fonck M, Béchade D, Bécouarn Y, Evrard S. Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only. PLoS One. 2015;10(3):e0122816. [PMC free article: PMC4380351] [PubMed: 25825874]
- 34.
Shida D, Yoshida T, Tanabe T, Tsukamoto S, Ochiai H, Kanemitsu Y. Prognostic Impact of R0 Resection and Targeted Therapy for Colorectal Cancer with Synchronous Peritoneal Metastasis. Ann Surg Oncol. 2018 Jun;25(6):1646-1653. [PubMed: 29572704]
- 35.
Shida D, Tsukamoto S, Ochiai H, Kanemitsu Y. Long-Term Outcomes After R0 Resection of Synchronous Peritoneal Metastasis from Colorectal Cancer Without Cytoreductive Surgery or Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2018 Jan;25(1):173-178. [PubMed: 29063295]
- 36.
Repullo DJ, Barbois S, Leonard D, Bohlok A, Van den Audenaeren ET, Hendlisz A, Van den Eynde M, Donckier V, Kartheuser A, Liberale G. The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis. Eur J Surg Oncol. 2021 Jul;47(7):1661-1667. [PubMed: 33602530]
- 37.
Gronau F, Jara M, Feldbrügge L, Wolf V, Oeff A, Rau B. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer]. Chirurg. 2021 Jun;92(6):522-527. [PubMed: 33620502]
- 38.
Rosa F, Galiandro F, Ricci R, Di Miceli D, Longo F, Quero G, Tortorelli AP, Alfieri S. Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center. Langenbecks Arch Surg. 2021 Jun;406(4):1071-1080. [PMC free article: PMC8208915] [PubMed: 33611693]
- 39.
Lei Z, Wang J, Li Z, Li B, Luo J, Wang X, Wang J, Ba M, Tang H, He Q, Liao Q, Yang X, Guan T, Liang H, Cui S, On Behalf Of The Chinese Peritoneal Oncology Study Group Hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: A multicenter propensity score-matched cohort study. Chin J Cancer Res. 2020 Dec 31;32(6):794-803. [PMC free article: PMC7797229] [PubMed: 33447001]
Disclosure: Mohammed Ben Aziz declares no relevant financial relationships with ineligible companies.
Disclosure: Raffaela Di Napoli declares no relevant financial relationships with ineligible companies.
